A Study of TMC435350 Administered With or Without Standard of Care Therapy in Participants With Genotype 1 Hepatitis C Virus Infection

NCT00561353 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: TMC435
DRUG: Placebo
DRUG: Peginterferon (PegIFNα-2a)
DRUG: Ribavirin

Sponsor

Tibotec Pharmaceuticals, Ireland